Clinical Trial Update: A Study of mDCF in Combination or Not With Atezolizumab in Advanced Squamous Cell Anal Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the modified DCF chemotherapy regimen (mDCF) with or without atezolizumab in advanced squamous cell anal carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anal Cancer

Drugs mentioned

• Atezolizumab (atezolizumab)
• Modified DCF chemotherapy regimen (mDCF) (modified docetaxel, cisplatin, and 5-fluorouracil regimen)

Snippet

Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group | Conditions: Anal Cancer | Phase 2 | Status: COMPLETED